Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cortical morphology predicts placebo response in multiple sclerosis.
Cherkasova MV, Fu JF, Jarrett M, Johnson P, Abel S, Tam R, Rauscher A, Sossi V, Kolind S, Li DKB, Sadovnick AD, Machan L, Girard JM, Emond F, Vosoughi R, Traboulsee A, Stoessl AJ. Cherkasova MV, et al. Among authors: vosoughi r. Sci Rep. 2022 Jan 14;12(1):732. doi: 10.1038/s41598-021-04462-7. Sci Rep. 2022. PMID: 35031632 Free PMC article.
Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial.
Traboulsee AL, Machan L, Girard JM, Raymond J, Vosoughi R, Hardy BW, Emond F, Gariepy JL, Bone JN, Siskin G, Klass D, Isserow S, Illes J, Sadovnick AD, Li DK. Traboulsee AL, et al. Among authors: vosoughi r. Neurology. 2018 Oct 30;91(18):e1660-e1668. doi: 10.1212/WNL.0000000000006423. Epub 2018 Sep 28. Neurology. 2018. PMID: 30266886 Free PMC article. Clinical Trial.
Use of natalizumab in persons with multiple sclerosis: 2022 update.
Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, Vosoughi R. Morrow SA, et al. Among authors: vosoughi r. Mult Scler Relat Disord. 2022 Sep;65:103995. doi: 10.1016/j.msard.2022.103995. Epub 2022 Jun 26. Mult Scler Relat Disord. 2022. PMID: 35810718 Free article. Review.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Therapy of MS.
Vosoughi R, Freedman MS. Vosoughi R, et al. Clin Neurol Neurosurg. 2010 Jun;112(5):365-85. doi: 10.1016/j.clineuro.2010.03.010. Epub 2010 Apr 1. Clin Neurol Neurosurg. 2010. PMID: 20362388 Review.
Characteristics of COVID-19 disease in multiple sclerosis patients.
Barzegar M, Mirmosayyeb O, Ghajarzadeh M, Nehzat N, Vaheb S, Shaygannejad V, Vosoughi R. Barzegar M, et al. Among authors: vosoughi r. Mult Scler Relat Disord. 2020 Oct;45:102276. doi: 10.1016/j.msard.2020.102276. Epub 2020 Jun 8. Mult Scler Relat Disord. 2020. PMID: 32652473 Free PMC article. No abstract available.
26 results